BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 36345617)

  • 1. Immune scoring model based on immune cell infiltration to predict prognosis in diffuse large B-cell lymphoma.
    Yang J; Yu L; Man J; Chen H; Zhou L; Zhao L
    Cancer; 2023 Jan; 129(2):235-244. PubMed ID: 36345617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
    Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
    Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
    Xiong D; Wei X; Huang W; Zheng J; Feng R
    Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
    Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
    Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel NET-related gene signature for predicting DLBCL prognosis.
    Shi H; Pan Y; Xiang G; Wang M; Huang Y; He L; Wang J; Fang Q; Li L; Liu Z
    J Transl Med; 2023 Sep; 21(1):630. PubMed ID: 37716978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment.
    Cui Y; Leng C
    Front Cell Dev Biol; 2023; 11():1070777. PubMed ID: 36755971
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
    Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
    Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma.
    Zhou H; Zheng C; Huang DS
    PeerJ; 2020; 8():e9658. PubMed ID: 32844062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
    Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
    Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.
    Wu Z; Guan Q; Han X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Wang X; Zhang H
    Aging (Albany NY); 2021 Oct; 13(19):22947-22962. PubMed ID: 34610582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel model based on ferroptosis-related genes for predicting the prognosis of diffuse large B-cell lymphomas.
    Wang J; Peng H; Zhang G; Yan W
    Hematology; 2023 Dec; 28(1):2198862. PubMed ID: 37199349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of
    Xiang X; Gao LM; Zhang Y; Tang Y; Zhao S; Liu W; Ye Y; Zhang W
    Front Genet; 2022; 13():849422. PubMed ID: 35711924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel telomere-related genes model for predicting prognosis and treatment responsiveness in diffuse large B-cell lymphoma.
    Zhao Z; Shen X; Zhao S; Wang J; Tian Y; Wang X; Tang B
    Aging (Albany NY); 2023 Nov; 15(22):12927-12951. PubMed ID: 37976136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
    He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
    J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
    Liu Y; Wang J; Shen X; Li L; Zhang N; Wang X; Tang B
    Clin Exp Med; 2023 Nov; 23(7):3781-3797. PubMed ID: 37402040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic immune risk score for diffuse large B-cell lymphoma.
    Ma SY; Tian XP; Cai J; Su N; Fang Y; Zhang YC; Wang JN; Peter Gale R; Cai QQ
    Br J Haematol; 2021 Jul; 194(1):111-119. PubMed ID: 33942291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma.
    Pan YB; Wang W; Cai HK; Zhang J; Teng Y; Xue J; Zhu M; Luo WD
    Front Genet; 2022; 13():911443. PubMed ID: 36035126
    [No Abstract]   [Full Text] [Related]  

  • 19. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
    Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
    J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
    Zhang Q; Zhu Z; Guan J; Zheng C
    Front Oncol; 2022; 12():904614. PubMed ID: 35814424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.